CT20 Peptide Binding CCT to Inhibit Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic breast cancers, particularly triple-negative breast cancer, are ineffective due to the unknown molecular basis, leading to a need for compositions and methods that prevent or inhibit metastasis and target cancer stem cells or cells undergoing epithelial-to-mesenchymal transition.
Innovation Solution
A method involving the measurement of chaperonin containing TCP (CCT) levels in a subject's sample, with the administration of a CT20 peptide that binds to CCT, potentially delivered via nanoparticles, to initiate a therapeutic regimen that includes anti-cancer agents, targeting cancer cells while sparing non-cancerous cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If standard chemotherapy and molecular-targeted biological agents are used to treat metastatic breast cancer, then treatment options are provided, but overall survival is not improved
Solution Approach 1:
The CT20 peptide acts as an intermediary molecule that binds to CCT (chaperonin containing TCP) in cancer cells, serving as a selective mediator to deliver therapeutic effects. This intermediary approach allows targeted intervention in cancer cell metabolism without the broadside effects of conventional chemotherapy, thereby improving survival rates while maintaining treatment options.
Solution Approach 2:
The invention changes the molecular parameter by targeting CCT, a specific protein involved in protein folding and chaperoning within cancer cells. By altering the therapeutic focus from general cell killing to specific molecular target disruption, the treatment achieves improved overall survival while maintaining adaptability through peptide-based precision medicine.
2Object-affected harmful factors
If conventional chemotherapy is administered to kill cancer cells, then cancer cells are destroyed, but non-cancerous cells are also affected
Solution Approach 1:
The CT20 peptide exhibits local quality by selectively binding to CCT proteins that are specifically expressed or overexpressed in cancer cells. This selective binding creates a localized therapeutic effect that destroys cancer cells while sparing non-cancerous cells, as the peptide does not recognize or bind to CCT in normal tissues.
Solution Approach 2:
The CT20 peptide serves as a selective intermediary that mediates the therapeutic effect specifically in cancer cells. By acting as a targeted mediator that recognizes CCT in cancer cells but not in normal cells, it enables cancer cell destruction without the harmful side effects of conventional non-selective chemotherapy.
3Loss of information
If the molecular basis of triple-negative breast cancer is investigated, then treatment targets may be identified, but the molecular basis remains unknown
Solution Approach 1:
The invention performs preliminary action by identifying and targeting CCT as a molecular basis for triple-negative breast cancer treatment. Before comprehensive molecular characterization is complete, the CT20 peptide targets a specific functional protein (CCT) that is known to be involved in cancer cell survival, thereby enabling effective treatment while molecular research continues.
Solution Approach 2:
The CT20 peptide acts as an intermediary that bridges the gap between unknown molecular basis and effective treatment. By targeting CCT as a functional intermediary protein, the therapy achieves effectiveness without requiring complete molecular characterization, allowing treatment development to proceed independently of full molecular understanding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CT20 peptide effectively induces cancer cell death, including immunogenic cell death, and can be used to promote a cancer vaccine response, offering a potential treatment for various cancers by disrupting CCT functions, thereby inhibiting metastasis and improving treatment efficacy.
Implementation Method 1
the CT20 peptide is able to bind directly with CCT, which can include hydrophobic interactions
Data Source
AI summary
Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT).